Evaluating Value of BTK Inhibitors in CLL Treatment

With a 42% reduction seen in the use of hematopoietic stem cell transplantation (HSCT) throughout the decade, researchers suggest that transplantation may be reserved for more fit patients.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).